Table 1.
Main clinical and laboratory characteristics of the entire study population and by sex.
| Clinical and Laboratory Data | Hemodynamic Data | ||||||
|---|---|---|---|---|---|---|---|
| Entire Cohort (N. 1503) |
Men (N. 720) |
Women (N. 783) |
Entire Cohort (N. 1503) |
Men (N. 720) |
Women (N. 783) |
||
| Age (years) | 58 ± 16 | 58 ± 15 | 58 ± 16 | SBP (mmHg) | 141.0 ± 10.4 | 140.8 ± 8.5 | 141.2 ± 12.8 |
| BMI (kg/m2) | 26.7 ± 4.6 | 27.1 ± 3.9 | 26.3 ± 5.1 | DBP (mmHg) | 73.5 ± 5.7 | 75.3 ± 5.7 | 71.9 ± 5.5 * |
| LDL-C (mg/dL) | 140 ± 27 | 137 ± 26 | 143 ± 27 | MAP (mmHg) | 96.1 ± 8.5 | 97.2 ± 7.5 | 94.9 ± 8.4 |
| TG (mg/dL) | 119 ± 70 | 126 ± 79 | 111 ± 60 | PP (mmHg) | 67.5 ± 6.5 | 65.4 ± 4.3 | 69.3 ± 8.7 * |
| HDL-C (mg/dL) | 52 ± 12 | 48 ± 11 | 55 ± 12 * | Aortic BP (mmHg) | 137.9 ± 10.9 | 137.5 ± 8.6 | 138.3 ± 12.8 |
| FPG (mg/dL) | 96 ± 19 | 98 ± 21 | 93 ± 18 | Aortic PP (mmHg) | 64.4 ± 7.8 | 62.1 ± 4.2 | 66.4 ± 8.6 |
| SUA (mg/dL) | 5.3 ± 1.2 | 5.9 ± 1.1 | 4.7 ± 1.1 * | Augmentation Index | 25.6 ± 6.9 | 24.3 ± 6.8 | 26.8 ± 6.9 |
| Creatinine (mg/dL) | 1.0 ± 0.2 | 1.1 ± 0.2 | 1.0 ± 0.2 | cfPWV (m/s) | 9.1 ± 2.4 | 9.2 ± 2.2 | 9.1 ± 2.5 |
| eGFR (mL/min) | 71 ± 16 | 73 ± 15 | 69 ± 15 | HR (bpm) | 64 ± 8 | 61 ± 7 | 66 ± 8 * |
* p < 0.05 versus men. BMI = body mass index, BP = blood pressure, cfPWV = carotid-femoral pulse wave velocity, DBP = diastolic blood pressure, eGFR = estimated glomerular filtration rate, FPG = fasting plasma glucose, HR = heart rate, MAP = mean arterial pressure, N = number of individuals, PP = pulse pressure, SBP = systolic blood pressure, SUA = serum uric acid, TG = triglycerides.